Development of diagnostic kits for fusion gene detection in haematooncology (Q10134): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The aim of the project is to develop prototypes of diagnostic kits for detection and quantification of fusion genes in hematooncology. In order to increase the performance parameters of the examination, innovations from oligonucleotide synthesis, mainly melting temperature modification and synthesis purification will be used. Real-time PCR, digital PCR and next generation sequencing will be used for the solution. By introducing these trains into...) |
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
||
| description / en | description / en | ||
Project in Czech Republic | Project Q10134 in Czech Republic | ||
| description / cs | description / cs | ||
Projekt v | Projekt Q10134 v Czechia | ||
Revision as of 15:38, 28 October 2020
Project Q10134 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of diagnostic kits for fusion gene detection in haematooncology |
Project Q10134 in Czech Republic |
Statements
10,223,960.0 Czech koruna
0 references
17,780,800.0 Czech koruna
0 references
57.5 percent
0 references
1 July 2016
0 references
29 September 2019
0 references
GENERI BIOTECH s.r.o.
0 references
50°11'18.20"N, 15°49'54.80"E
0 references
50011
0 references
Cílem projektu je vývoj prototypů diagnostických souprav pro detekci a kvantifikaci fúzních genů v hematoonkologii. Za účelem zvýšení výkonnostních parametrů vyšetření budou využity inovace z oblasti oligonukleotidových syntéz, převážně modifikace teploty tání a purifikace po syntéze. Pro řešení budou využity technologie real-time PCR, digitální PCR a sekvenování nové generace. Zavedením těchto souprav do nabídky očekáváme zvýšení konkurenceschopnosti firmy na českém i zahraničním trhu. a. (Czech)
0 references
The aim of the project is to develop prototypes of diagnostic kits for detection and quantification of fusion genes in hematooncology. In order to increase the performance parameters of the examination, innovations from oligonucleotide synthesis, mainly melting temperature modification and synthesis purification will be used. Real-time PCR, digital PCR and next generation sequencing will be used for the solution. By introducing these trains into the offer we expect to increase the competitiveness of the company on the Czech and foreign markets. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_018/0004927
0 references